Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 124, Issue 5, 1998, Pages 236-244

  Cividalli, Anna ^a   Cruciani, Giorgio ^b   Livdi, Esther ^b   Cordelli, Eugenia ^a   Eletti, Brighitta ^a   Tirindelli Danesi, Donatella ^a  

^a ENEA   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

Cell cycle; Murine mammary carcinoma; Paclitaxel epirubicin; Toxicity; Tumor growth delay

Indexed keywords

EPIRUBICIN; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA; BREAST ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSPNEA; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LETHARGY; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EPIRUBICIN; FEMALE; FLOW CYTOMETRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; PACLITAXEL; TIME FACTORS;

EID: 0031746874     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050160     Document Type: Article

References (42)

1. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Helmann S, Canetta R, Friedman MA, Arbuck SG (1995) Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center Trial. J Clin Oncol 13:2056-2065
2. Allen A (1992) The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529-542
3. Arbuck SG (1994) Taxol (paclitaxel): future directions. Ann Oncol 5 (S6):S59-S62
4. Bajorko P, Flamigni A, Volpi A, Fedriga R, Serra P, Milandri C, Flamini E. (1994) Carcinoma della mammella: valutazione in vitro della attività citotossica della associazione farmacologica di taxolo e adriamicina. XII Riunione Nazionale di Oncologia Sperimentale e Clinica, 23-26 ottobre. Tumori 80:107
5. Barranco SC (1986) Cellular and molecular effects of Adriamycin on dividing and nondividing cells. In: Dethlefsen LA (ed) Cell cycle effects of drugs. Pergamon, New York, pp 251-268
6. Cividalli A, Tirindelli Danesi D, Altavista P, Bonanni M, Persiani D, Segre L, Cruciani G (1995) 4′Epi-doxorubicin and hyperthermia in a murine mammary carcinoma: influence of the dose and fractionation. Anticancer Res 15:739-744
7. Colombo T, Gonzalez Paz O, Zucchetti M, Maneo M, Sessa C, Goldhirsch A, D'Incalci M (1996) Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 7:801-805
8. Corbett TH, Valeriote FA (1987) Rodents models in experimental chemotherapy. In: Kallman RF (ed) Rodent tumor models in experimental cancer therapy. Pergamon, Oxford, pp 233-247
9. Decorti G, Bartoli Klugmann F, Candussio L, Baldini L (1996) Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 16:317-320
10. cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5:1041-1050
11. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-desease small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 13:1430-1435
12. Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Locatelli A, Bonadonna G, Egorin MJ (1995a) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic pharmacodynamic relationships in humans. J Clin Oncol 13:180-190
13. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G (1995b) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699
14. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A, Valagussa P, Bonadonna G (1995c) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with desease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175
15. Gupta N, Hu LJ, Deen DF (1997) Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys 37:885-895
16. Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D (1993) Taxol in combination with doxorubicin or etoposide. Cancer 72:2705-2711
17. Holmes AF, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN (1996) Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721
18. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825
19. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68:1104-1109
20. Long BH, Fairchild CR (1994) Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 54:4355-4361
21. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242
22. Manfredi JJ, Horwitz SB (1986) Taxol: an antimitotic agent with a new mechanism of action. In: Dethlefsen LA (ed) Cell cycle effects of drugs. Pergamon, New York, pp 287-333
23. Markman M (1996) Paclitaxel in the management of ovarian cancer: whal we know and what we have yet to learn. J Cancer Res Clin Oncol 122:71-73
24. Markman M, Francis P, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL, Rubin S, Curtin J, Barakat R, Phillips M, Hoskins W (1994) Intraperitoneal taxol (paclitaxel) in the management of ovarian cancer. Ann Oncol 5 (S6):S55-S58
25. Mauro F, Cividalli A, Adami M, Pardini MC and Arcangeli G (1983) relative effectiveness of X-ray multifraction schedules: experiments on a murine tumor system in vivo. In: Broerse JJ, Barendsen GW, Kahl HB, Van der Kogel (eds) Proceeding of the 4th International Congress of Radiation Research (ICRR), Amsterdam, Nijhoff, Rijswijk, D1-22.
26. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ (1993) Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35:297-303
27. O'Shaughnessy JA, Fisherman JS, Cowan KH (1994) Combination paclitaxel (taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol 21:19-23
28. Otto F (1990) Dapi staining of fixed cells for high-resolution flow cytometry of nuclear DNA. In: Darziynkiewicz Z, Crissman HA (eds) Flow cytometry. Academic Press, San Diego, pp 105-110
29. Overgaard J (1980) Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surronding normal tissue in vivo. Int J Radiat Oncol Biol Phys 6:1507-1517
30. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A (1992) Transfer and expression of the human multiple drug resistence gene into live mice. Proc Natl Acad Sci USA 89:9676-9680
31. Pulkkinen JO, Elomaa L, Martikainen HJP, Servomaa C, Grénman R (1966) Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 122:214-218
32. Rantanen V, Grénman S, Kulmala J, Grénman R (1996) Endometrial cancer cell lines are sensitive to paclitaxel. Anticancer Res 16:475-480
33. Rose WC (1992) Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3:311-321
34. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646-662
35. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77 (S3):1561-1565
36. Seidman AD, Reichman BS, Crown JPA, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L (1995a) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159
37. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewsky T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tone W, Egorin M, Kearns C, Spriggs D, Norton L (1995b) Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy of metastatic breast cancer. J Clin Oncol 13:2575-2581
38. Sledge GW, Robert N, Sparano JA, Cobeligh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W (1994) Paclitaxel (Taxol)/doxorubicin combination in advanced breast cancer: the Eastern Cooperative Oncology Group Experience. Semin Oncol 21 (S5):S15-S18
39. Solis Recéndez MG, Grossin F, Bichat F (1996) Drugs interactions between Taxol (TAX) and Adriamycine (ADR) in mice: difference of ADR incorporation according to the schedule of administration. Proc Am Assoc Cancer Res 37:372
40. Spielmann M, Catimel G, Kayitalire E, Pouillart P, Dumortier A, Graffand N, Pellae-Cosset B (1995) Taxol (paclitaxel) and Farmorubicin (epirubicin) in metastatic breast cancer (MBC) preliminary results of a phase I study. Eur J Cancer S 80
41. Webster LK, Cosson EJ, Stokes KH, Millward MJ (1996) Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73:522-524
42. Wilson HW, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM, Chabner BA (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629